Immunotherapy prolonged survival compared with platinum chemotherapy.
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Researchers sought to determine the effectiveness of nivolumab, identify predictors of early discontinuation of treatment among patients with NSCLC, and determine median OS of nivolumab and docetaxel.
Pooled odds ratios for lung cancer increased with emphysema severity, and were higher for visual versus quantitative assessments on chest CT.
Segmentectomy prolonged 5-year overall survival in a phase 3 trial.